Atara Biotherap (ATRA) Stock Price, Quote & News

Company Profile

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Ket...

Industry: Biotechnology

Sector: Healthcare

Phone: 805 623 4211

Website: www.atarabio.com

Address:

1280 Rancho Conejo Blvd, Thousand Oaks, United States

Ulong Aug. 20 at 8:36 AM

$ATRA 👇👇👇

1 · Reply

aitrades23 Aug. 20 at 2:50 AM

$ATRA

0 · Reply

Stockslingin Aug. 20 at 2:46 AM

$ATRA

0 · Reply

AlertsAndNews Aug. 20 at 2:44 AM

$ATRA Atara Biotherapeutics: James Huang (Director, 10%+) Buys 55,000 Shares at $12.19 Avg – Form 4 Director James Huang disclosed the purchase of 55,000 shares, totaling roughly $670K.

1 · Reply

SumDay1Day Aug. 19 at 4:58 PM

$ATRA Next leg coming to you soon? 15$? Or 10$?

1 · Reply

Doozio Aug. 16 at 10:32 AM

$ATRA here’s comes Roger in RYTM n HRMY n he’s gonna be LGNDary during 🐒🍌🧠⏰♾️

0 · Reply

takingstock73 Aug. 15 at 12:44 AM

$ATRA anyone know why an after hours trading action like the one today would show up here but not on cnbc app?

0 · Reply

Smurfologist Aug. 12 at 4:16 PM

$ATRA Rocket Boosters ACTIVATED🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀

0 · Reply

Smurfologist Aug. 12 at 4:02 PM

Well, ok then......Can $ATRA hit $12.75?!? I believe it can!!! 🙏🏾🐃💪🏾💣💥🚀

0 · Reply

Smurfologist Aug. 12 at 4:01 PM

Can $ATRA hit $12.25 today?!? LET'S SEE (in my Jerry Springer voice)!!!🙏🏾🐃💪🏾💣💥🚀

0 · Reply

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

Jul 24, 2025, 8:57 AM EDT - 27 days ago

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Jul 24, 2025, 8:00 AM EDT - 27 days ago

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Jul 15, 2025, 8:00 AM EDT - 5 weeks ago

Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.

Jul 14, 2025, 8:00 AM EDT - 5 weeks ago

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

May 16, 2025, 8:50 PM EDT - 3 months ago

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

May 15, 2025, 8:35 AM EDT - 3 months ago

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

May 15, 2025, 8:30 AM EDT - 3 months ago

Atara Biotherapeutics Announces Pricing of $16 Million Offering

May 5, 2025, 5:06 PM EDT - 3 months ago

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

Mar 7, 2025, 4:01 PM EST - 5 months ago

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

Mar 1, 2025, 11:00 AM EST - 6 months ago

The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Feb 15, 2025, 11:00 AM EST - 6 months ago

The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Feb 14, 2025, 8:11 AM EST - 6 months ago

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

Feb 11, 2025, 7:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation

Feb 10, 2025, 7:00 AM EST - 6 months ago

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Feb 9, 2025, 7:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation

Feb 7, 2025, 4:01 PM EST - 6 months ago

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 7:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect

Feb 6, 2025, 7:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect

Feb 5, 2025, 7:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation

Feb 4, 2025, 7:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation

Feb 3, 2025, 11:00 AM EST - 7 months ago

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Atara Biotherapeutics, Inc. For Securities Fraud

Feb 3, 2025, 7:00 AM EST - 7 months ago

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 31, 2025, 7:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation

Jan 30, 2025, 7:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation

Jan 29, 2025, 7:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out

Jan 28, 2025, 11:00 AM EST - 7 months ago

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Atara Biotherapeutics, Inc. For Securities Fraud

Jan 28, 2025, 7:00 AM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out

Jan 28, 2025, 3:23 AM EST - 7 months ago

ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Jan 27, 2025, 8:30 PM EST - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect

Jan 21, 2025, 1:11 PM EST - 7 months ago

FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs

Jan 21, 2025, 7:30 AM EST - 7 months ago

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

Jan 21, 2025, 12:21 AM EST - 7 months ago

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

Jan 16, 2025, 8:41 AM EST - 7 months ago

US FDA declines to approve Atara Biotherapeutics' cancer therapy

Jan 16, 2025, 8:30 AM EST - 7 months ago

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

Nov 27, 2024, 4:01 PM EST - 9 months ago

Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference

Nov 13, 2024, 4:01 PM EST - 10 months ago

Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference

Ulong Aug. 20 at 8:36 AM

$ATRA 👇👇👇

1 · Reply

aitrades23 Aug. 20 at 2:50 AM

$ATRA

0 · Reply

Stockslingin Aug. 20 at 2:46 AM

$ATRA

0 · Reply

AlertsAndNews Aug. 20 at 2:44 AM

$ATRA Atara Biotherapeutics: James Huang (Director, 10%+) Buys 55,000 Shares at $12.19 Avg – Form 4 Director James Huang disclosed the purchase of 55,000 shares, totaling roughly $670K.

1 · Reply

SumDay1Day Aug. 19 at 4:58 PM

$ATRA Next leg coming to you soon? 15$? Or 10$?

1 · Reply

Doozio Aug. 16 at 10:32 AM

$ATRA here’s comes Roger in RYTM n HRMY n he’s gonna be LGNDary during 🐒🍌🧠⏰♾️

0 · Reply

takingstock73 Aug. 15 at 12:44 AM

$ATRA anyone know why an after hours trading action like the one today would show up here but not on cnbc app?

0 · Reply

Smurfologist Aug. 12 at 4:16 PM

$ATRA Rocket Boosters ACTIVATED🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀

0 · Reply

Smurfologist Aug. 12 at 4:02 PM

Well, ok then......Can $ATRA hit $12.75?!? I believe it can!!! 🙏🏾🐃💪🏾💣💥🚀

0 · Reply

Smurfologist Aug. 12 at 4:01 PM

Can $ATRA hit $12.25 today?!? LET'S SEE (in my Jerry Springer voice)!!!🙏🏾🐃💪🏾💣💥🚀

0 · Reply

Smurfologist Aug. 12 at 3:54 PM

Now, this is whut um talkin' 'bout, $ATRA!!! Smack dem Shorts in dey mouf HARD!!! LET'S GO, DAMN IT!!!🙏🏾💪🏾🐃💣💥🚀

0 · Reply

SumDay1Day Aug. 12 at 3:27 PM

$TGE and $ATRA want to actually have a good day today. I want to buy another 500 shares of TGE but i need to make sure we have a floor first. Staying optimistic.

0 · Reply

ballyhooo Aug. 11 at 8:14 PM

$ATRA Atara Biotherapeutics Q2 EPS $0.19 Beats $(0.81) Estimate, Sales $17.57M Beat $5.67M Estimate

1 · Reply

ballyhooo Aug. 11 at 8:09 PM

$ATRA Tab-cel Prescription Drug User Fee Act (PDUFA) Target Action Date of January 10, 2026 Atara has transferred substantially all operational activities and associated costs related to tab-cel to Pierre Fabre Laboratories Atara has resumed its evaluation of strategic options

0 · Reply

Smurfologist Aug. 8 at 11:26 AM

Will this be the day that $ATRA pushes over $12.00?!? LET'S GO, DAMN IT!!!🙏🏾🐃💪🏾💣💥🚀

0 · Reply

jjangles123 Aug. 7 at 6:20 PM

$MIST take a look at $ATRA how they recovered from CRL in Jan and an offering in May. Very similar stories. And now we see 75% gain from 6$ lows to now around 10$. Both companies had CRL rejection due to third party not drug efficacy. Following this pattern I think we could definitely be at 2.50-3.00$ leading into December.

1 · Reply

takingstock73 Aug. 4 at 12:10 PM

$ATRA let's go, been quiet here , when do we push back to 18?

0 · Reply

Smurfologist Aug. 1 at 2:20 AM

$ATRA is smacking dem Shorters in dey mouf hard in the After Market Trading Session......LUVIN' IT🙏🏾🐃💪🏾💣💥🚀

0 · Reply

Smurfologist Jul. 30 at 4:56 PM

$ATRA is showin' out for them doubters out there; YOU BETTA RECOGNIZE!!! 🙏🏾🐃💪🏾💣💥🚀

0 · Reply

VENIVICI Jul. 25 at 6:49 PM

Holding $ATRA tight into quarterly earnings. 🍿🍿🍿

3 · Reply

Smurfologist Jul. 25 at 2:27 PM

$ATRA Stocks rise; stocks fall.....THAT'S WHUT STOCKS DO. When stocks do whut they do, what matters is whut YOU do!! Gonna stack my chips so that when this stock bounce up, my pockets will git phat!!! There will always be haters out there. You have to do YOU!! Good luck to those that will stick around for the prize!! 🙏🏾🐃💪🏾💣💥🚀

0 · Reply

Newe0815 Jul. 24 at 9:44 PM

$ATRA The run will now probably be over, the hope was probably on a Class 1 classification. Now there will be nothing to report until January.

1 · Reply

Market Cap	80.62M
Revenue (ttm)	128.94M
Net Income (ttm)	-85.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-66.23%
Debt to Equity Ratio	0.00

Volume	64,500
Avg Vol	52,414
Day's Range	N/A - N/A
Shares Out	7.02M
Stochastic %K	66%
Beta	0.26
Analysts	Sell
Price Target	$13.33